Antimetabolitlerin Etki Mekanizmaları ve Sınıflandırılması
Özet
Bu çalışma, kanser tedavisinde kullanılan antimetabolitlerin etki mekanizmalarını ve sınıflandırılmasını detaylı bir şekilde ele almaktadır. Antimetabolitler, hücre büyümesi ve çoğalmasında kritik rol oynayan nükleik asit ile proteinlerin sentezini engelleyerek biyosentez inhibisyonu yapan döneme özgü ilaçlardır. En fazla S fazında etkinlik gösteren bu ajanlar, hızlı çoğalan tüm hücreleri seçici olmayan bir yaklaşımla hedef alırlar. Makalede antimetabolitler üç temel grupta sınıflandırılmıştır: Folik asit antimetabolitleri, pürin analogları ve pirimidin analogları. Metotreksat ve pemetrekset gibi folik asit antimetabolitleri, dihidrofolat redüktaz ve timidilat sentaz gibi kritik enzimleri inhibe ederek DNA ve RNA sentezini bloke eder. 6-merkaptopürin, fludarabin ve kladribin gibi pürin analogları, nükleotid prekürsörlerinin oluşumunu bozarak sitotoksik etki yaratır. 5-fluorourasil, sitarabin ve gemsitabin gibi pirimidin analogları ise DNA onarımını ve protein sentezini engellemektedir. Çalışmada ayrıca bu ajanların farmakokinetik özellikleri, klinik kullanım alanları (lösemi, lenfoma, meme ve akciğer kanserleri gibi) ve tedavi sırasında tümör hücrelerinin geliştirdiği direnç mekanizmaları kapsamlıca açıklanmıştır.
This study comprehensively evaluates the mechanisms of action and classification of antimetabolites utilized in cancer treatment. Antimetabolites are cell-cycle-specific drugs that induce biosynthesis inhibition by interfering with the synthesis of proteins and nucleic acids essential for cellular growth and replication. Exhibiting their maximum efficiency during the S phase, these agents non-selectively target all rapidly proliferating cells. Within the text, antimetabolites are categorized into three primary groups: Folic acid antimetabolites, purine analogs, and pyrimidine analogs. Folic acid antimetabolites, including methotrexate and pemetrexed, block DNA and RNA synthesis by inhibiting critical enzymes such as dihydrofolate reductase and thymidylate synthase. Purine analogs, such as 6-mercaptopurine, fludarabine, and cladribine, exert cytotoxic effects by disrupting the formation of nucleotide precursors. Pyrimidine analogs, including 5-fluorouracil, cytarabine, and gemcitabine, impair DNA repair mechanisms and protein synthesis. Furthermore, the study elucidates the pharmacokinetic profiles, clinical indications—ranging from leukemias and lymphomas to breast and lung malignancies—and the complex drug resistance mechanisms developed by tumor cells.
Referanslar
Kayaalp so (2005). Tıbbi Farmakoloji, Hacettepe Taş Yayınları, Ankara.
Casciato, DA, (2004). Cancer Chemotherapeutic Agents. In Casciato DA (ed, by), Manual of Clinical Oncology, Lippincott Williams & Wilkins, Philadelphia
Türker FA, Dizdar Ö, Meslek İçi Sürekli Eğitim Dergisi, https://www.e-kutuphane.teb.org.tr › eylul05 › 7.pdf
Kummar s et al (2005), Antimetabolites In De Vita VT Jr, Hellmans, Rosenberg SA (ed, by), Cancer Principals And Practice Of Oncology, Lippincott Williams & Wilkins, Philadelphia
Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG (October 2002). "Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics". Proceedings of the National Academy of Sciences of the United States of America. 99 (21): 13481-6.
Goodsell DS (August 1999). "The molecular perspective: methotrexate". The Oncologist. 4 (4): 340–1.
McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S, Spicer D, Bissett D, Pithavala YK, Collier MA, Paradiso LJ, Roberts JD (July 2000). "Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034". Clinical Cancer Research; Clinical Trials. 6 (7): 2677–84.
Avendano, Carmen; Menendez, J. Carlos (April 2008). Medicinal Chemistry of Anticancer Drugs. Amsterdam: Elsevier. p. 37
Zaza G, Cheok M, Krynetskaia N, Thorn C, Stocco G, Hebert JM, et al. (September 2010). "Thiopurine pathway". Pharmacogenetics and Genomics. 20 (9): 573–4.
Stocco G, Pelin M, Franca R, De Iudicibus S, Cuzzoni E, Favretto D, et al. (April 2014). "Pharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase?". World Journal of Gastroenterology. 20 (13): 3534–41.
Fujita K, Sasaki Y (August 2007). "Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy". Current Drug Metabolism. 8 (6): 554–62.
Fludarabin "Fludarabine Phosphate". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
Helms RA, Quan DJ (2006). Textbook of Therapeutics: Drug and Disease Management. Lippincott Williams & Wilkins. p. 2309.
Thomas P.; Weissert, Robert (2011). "Cladribine". Clinical Neuropharmacology. 34 (1):28–35. Giovannoni, G (2017). "Cladribine to Treat Relapsing Forms of Multiple Sclerosis". Neurotherapeutics. 14 (4): 874–887.
Johnston, James B (2011). "Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia". Leukemia & Lymphoma. 52: 43–45.
Longley D. B.; Harkin D. P.; Johnston P. G. (May 2003). "5-fluorouracil: mechanisms of action and clinical strategies". Nat. Rev. Cancer. 3 (5): 330–8.
Álvarez, P.; Marchal, J. A.; Boulaiz, H.; Carrillo, E.; Vélez, C.; Rodríguez-Serrano, F.; Melguizo, C.; Prados, J.; Madeddu, R.; Aranega, A. (February 2012). "5-Fluorouracil derivatives: a patent review". Expert Opinion on Therapeutic Patents. 22 (2): 107–123.
Caudle, KE; Thorn, CF; Klein, TE; Swen, JJ; McLeod, HL; Diasio, RB; Schwab, M (December 2013). "Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing". Clinical Pharmacology and Therapeutics. 94 (6): 640–5.
Amstutz, U; Froehlich, TK; Largiadèr, CR (September 2011). "Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity". Pharmacogenomics. 12 (9): 1321–36.
Porta C, Moroni M, Nastasi G (1994). "Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis". Am. J. Clin. Oncol. 17 (3): 246–7.
Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M (December 2013). "Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing". Clinical Pharmacology and Therapeutics. 94 (6): 640–5.
Widemann BC, Balis FM, Godwin KS, McCully C, Adamson PC (1999). "The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model". Cancer Chemother. Pharmacol. 44 (6): 439–43.
Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M (December 2013). "Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing". Clinical Pharmacology and Therapeutics. 94 (6): 640–5.
Perry, Michael J. (2008). The Chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 80.
Martens UM, ed. (2010). "11 5-Azacytidine/Azacitidine". Small molecules in oncology. Recent Results in Cancer Research. Vol. 184. Heidelberg: Springer. pp. 159–170.
Alvarellos ML, Lamba J, Sangkuhl K, Thorn CF, Wang L, Klein DJ, Altman RB, Klein TE (November 2014). "PharmGKB summary: gemcitabine pathway". Pharmacogenetics and Genomics. 24 (11): 564–74.
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (May 2006). "Cellular pharmacology of gemcitabine". Annals of Oncology. 17 Suppl 5: v7-12.
Platt OS (2008). "Hydroxyurea for the treatment of sickle cell anemia". N. Engl. J. Med. 358 (13): 1362–9.
Yarbro JW (1992). "Mechanism of Action". Seminars in Oncology. 19 (3): 1–10.
